当前位置: X-MOL 学术Drug Resist. Updat. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Drug Resistance Updates ( IF 24.3 ) Pub Date : 2017-05-21 , DOI: 10.1016/j.drup.2017.05.002
Maya Bar-Zeev , Yoav D. Livney , Yehuda G. Assaraf

Intrinsic anticancer drug resistance appearing prior to chemotherapy as well as acquired resistance due to drug treatment, remain the dominant impediments towards curative cancer therapy. Hence, novel targeted strategies to overcome cancer drug resistance constitute a key aim of cancer research. In this respect, targeted nanomedicine offers innovative therapeutic strategies to overcome the various limitations of conventional chemotherapy, enabling enhanced selectivity, early and more precise cancer diagnosis, individualized treatment as well as overcoming of drug resistance, including multidrug resistance (MDR). Delivery systems based on nanoparticles (NPs) include diverse platforms enabling a plethora of rationally designed therapeutic nanomedicines. Here we review NPs designed to enhance antitumor drug uptake and selective intracellular accumulation using strategies including passive and active targeting, stimuli-responsive drug activation or target-activated release, triggered solely in the cancer cell or in specific organelles, cutting edge theranostic multifunctional NPs delivering drug combinations for synergistic therapy, while facilitating diagnostics, and personalization of therapeutic regimens. In the current paper we review the recent findings of the past four years and discuss the advantages and limitations of the various novel NPs-based drug delivery systems. Special emphasis is put on in vivo study-based evidences supporting significant therapeutic impact in chemoresistant cancers. A future perspective is proposed for further research and development of complex targeted, multi-stage responsive nanomedical drug delivery systems for personalized cancer diagnosis and efficacious therapy.



中文翻译:

针对癌症治疗的靶向纳米药物:迈向克服耐药性的精密药物

化疗之前出现的内在抗癌药耐药性以及由于药物治疗而获得的耐药性仍然是治愈性癌症治疗的主要障碍。因此,克服癌症耐药性的新型靶向策略构成了癌症研究的主要目标。在这方面,靶向纳米药物提供了创新的治疗策略,可以克服常规化学疗法的各种局限性,从而提高选择性,早期和更精确的癌症诊断,个性化治疗以及克服包括多药耐药性(MDR)在内的耐药性。基于纳米颗粒(NPs)的输送系统包括多种平台,可实现大量合理设计的治疗性纳米药物。在这里,我们回顾了旨在增强抗肿瘤药物摄取和选择性细胞内蓄积的NPs,这些策略包括被动和主动靶向,刺激响应性药物激活或靶标激活释放,仅在癌细胞或特定细胞器中触发,尖端的治疗性多功能NPs递送协同治疗的药物组合,同时有助于诊断和治疗方案的个性化。在本文中,我们回顾了过去四年的最新发现,并讨论了各种基于NP的新型药物递送系统的优势和局限性。特别强调 先进的治疗性多功能NP可以提供药物组合用于协同治疗,同时有助于诊断和治疗方案的个性化。在本文中,我们回顾了过去四年的最新发现,并讨论了各种基于NP的新型药物递送系统的优势和局限性。特别强调 先进的治疗性多功能NP可以提供药物组合用于协同治疗,同时有助于诊断和治疗方案的个性化。在本文中,我们回顾了过去四年的最新发现,并讨论了各种基于NP的新型药物递送系统的优势和局限性。特别强调体内研究为基础的证据支持对化学耐药性癌症的重大治疗作用。为进一步研究和开发用于个性化癌症诊断和有效治疗的复杂靶向,多阶段响应性纳米药物给药系统,提出了未来的观点。

更新日期:2017-05-21
down
wechat
bug